WALLDORF — SAP SE (NYSE: SAP) today announced its industry-leading pharmaceutical supply chain solutions are the recipients of a 2019 Frost & Sullivan Visionary Innovation Leadership Award.
In addition, the SAP Advanced Track and Trace for Pharmaceuticals application and SAP Information Collaboration Hub for Life Sciences won recognition in the Digital Enterprise Solutions for the Pharma Supply Chain category.
Each year, the Frost & Sullivan Visionary Innovation Leadership Award recognizes a range of regional and global companies that encourage significant growth in their industries, identify emerging trends before they become the marketplace standard, and create advanced technologies that transform industries in the near future.
Counterfeit prescriptions introduced into the drug value chain have been a massive problem, impacting public safety on a global scale. The blockchain software technology hub in SAP Information Collaboration Hub for Life Sciences, together with SAP Advanced Track and Trace for Pharmaceuticals, helps ensure compliance with global serialization requirements and supports a concerted effort to eliminate counterfeit in the pharmaceutical supply chain. Specifically, blockchain-based SAP Information Collaboration Hub for Life Sciences is designed to authenticate pharmaceutical packaging returned to wholesalers from hospitals and pharmacies before products are resold. It provides customers with a scalable and secure solution to comply with the upcoming regulatory requirements for verification. The software was developed in co-innovation with customers including AmerisourceBergen, Boehringer Ingelheim AG & Co. KG, GlaxoSmithKline plc and Merck Sharp & Dohme.
“SAP has truly set the standard for how intelligent technology can be an invaluable tool in combatting drug counterfeits and promoting compliance with global sterilization regulations,” said Frost & Sullivan Industry Analyst Kamaljit Behera. “We applaud the innovation SAP’s pharmaceutical supply chain solutions bring to the industry.”
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
2019 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.